ライフサイエンスコーパス: ritonavir

1 darunavir, and lopinavir (administered with ritonavir).

2 ceived darunavir/ritonavir and 44% lopinavir/ritonavir.

3 re total and subcutaneous fat than darunavir/ritonavir.

4 udine/lamivudine and nelfinavir or lopinavir/ritonavir.

5 ir was superior to once-daily darunavir plus ritonavir.

6 es did not prevent inactivation of CYP3A4 by ritonavir.

7 previr with JNJ-56914845 60 mg and TMC647055/ritonavir.

8 tched from lopinavir/ritonavir to atazanavir/ritonavir.

9 ir 50 mg once daily or darunavir 800 mg plus ritonavir 100 mg once daily, with investigator-selected

10 al therapy consisted of lopinavir 400 mg and ritonavir 100 mg plus lamivudine 150 mg, both twice dail

11 le therapy consisted of lopinavir 400 mg and ritonavir 100 mg twice daily and lamivudine or emtricita

12 All subjects received darunavir 800 mg, ritonavir 100 mg, and emtricitabine 200 mg daily.

13 l ombitasvir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg, plus twice-daily oral dasabuvir 250 mg

14 ed protease inhibitor (lopinavir 400 mg with ritonavir 100 mg, twice per day) plus two or three clini

15 dolutegravir 50 mg or darunavir 800 mg plus ritonavir 100 mg, with investigator-selected combination

16 afety of darunavir (800 mg once per day) and ritonavir (100 mg once per day) plus either raltegravir

17 bitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once daily for 12 weeks (without cirr

18 g administration of atazanavir (300 mg) plus ritonavir (100 mg) or lopinavir/ritonavir (800/200 mg) w

19 svir (25 mg) plus paritaprevir (150 mg) plus ritonavir (100 mg) with or without weight-based ribaviri

20 3) began treatment with atazanavir (300 mg), ritonavir (100 mg), emtricitabine (200 mg), and tenofovi

21 ibitor monotherapy (PI-mono); we recommended ritonavir (100 mg)-boosted darunavir (800 mg) once daily

22 mg)-boosted darunavir (800 mg) once daily or ritonavir (100 mg)-boosted lopinavir (400 mg) twice dail

23 mg twice daily; or darunavir, 800 mg/d, with ritonavir, 100 mg/d, plus combination emtricitabine, 200

24 Atazanavir, 300 mg/d, with ritonavir, 100 mg/d; raltegravir, 400 mg twice daily; or

25 ombitasvir (25 mg once daily), paritaprevir/ritonavir (150/100 mg once daily), and dasabuvir (250 or

26 Panel 4: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 30 mg once daily (Arm 1:

27 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day;

28 ; GT1b): simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg without ribavirin; Panel 3: simeprevir 7

29 adults were randomly assigned to atazanavir/ritonavir 300/100 mg or darunavir/ritonavir 800/100 mg i

30 tonavir (800/100 mg once daily) or lopinavir/ritonavir (400/100 mg twice daily) monotherapy, fasting

31 ART included lopinavir/ritonavir (400/100 mg) twice daily and emtricitabine/ten

32 ive oral ritonavir-boosted lopinavir (100 mg ritonavir, 400 mg lopinavir) plus 400 mg raltegravir twi

33 Panel 3: simeprevir 75 mg + TMC647055 600 mg/ritonavir 50 mg with (Arm 1: GT1a; n = 7) or without (Ar

34 tegravir 41 [17%] patients vs darunavir plus ritonavir 70 [29%] patients), nausea (39 [16%] vs 43 [18

35 atazanavir/ritonavir 300/100 mg or darunavir/ritonavir 800/100 mg in combination with tenofovir/emtri

36 lthy adult volunteers received (1) darunavir/ritonavir (800 mg/100 mg once daily) with and without fa

37 es/mL during >/=6 months on stable darunavir/ritonavir (800/100 mg once daily) or lopinavir/ritonavir

38 300 mg) plus ritonavir (100 mg) or lopinavir/ritonavir (800/200 mg) with the 3D regimen is not recomm

39 he basis of our investigations of analogs of ritonavir, a potent CYP3A4 inactivator and pharmacoenhan

40 ation of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the NS5A inhibitor ombitasvir

41 interferon-free combination of ABT-450 with ritonavir (ABT-450/r), ombitasvir (also known as ABT-267

42 The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or

43 ation of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhi

44 ation of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir (AB

45 ree regimen of ombitasvir, paritaprevir, and ritonavir, achieved high rates of SVR12 in patients with

46 bitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir (with or without

47 bitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks.

48 combination of ombitasvir, paritaprevir, and ritonavir, administered with dasabuvir, led to an SVR12

49 As a result, ritonavir adopts a distinctly different conformation to

50 n starting unboosted atazanavir or lopinavir/ritonavir among those with a low risk score was 1,702 (9

51 cation complex inhibitor), paritaprevir, and ritonavir (an NS3/4A protease inhibitor)-an interferon-

52 s or longer on triple therapy with darunavir/ritonavir and 2 nucleos(t)ides (tenofovir disoproxil fum

53 4 received ombitasvir plus paritaprevir plus ritonavir and 42 received ombitasvir plus paritaprevir p

54 46 subjects enrolled, 56% received darunavir/ritonavir and 44% lopinavir/ritonavir.

55 Seven patients discontinued atazanavir/ritonavir and 5 discontinued darunavir/ritonavir due to

56 At 96 weeks, 56 (62%) atazanavir/ritonavir and 62 (71%) darunavir/ritonavir patients rema

57 l [CI], -.6 to 21.6) and 71 (79%) atazanavir/ritonavir and 75 (85%) darunavir/ritonavir patients rema

58 Cytochrome P450 3A4 (CYP3A4) inhibitors ritonavir and cobicistat, currently administered to HIV

59 ound no major differences between atazanavir/ritonavir and darunavir/ritonavir in efficacy, clinicall

60 city of the side group analogous to Phe-2 of ritonavir and demonstrated the leading role of hydrophob

61 nue therapy (n = 128) or switch to darunavir/ritonavir and lamivudine (n = 129).

62 oninferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with

63 Dual therapy with darunavir/ritonavir and lamivudine demonstrated noninferior therap

64 and in vivo studies indicated that HIV PIs (ritonavir and lopinavir) significantly increased hepatic

65 However, evening atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recom

66 e-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir) and dasabuvir (250 m

67 e-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), and dasabuvir (250

68 e-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), dasabuvir (250 mg t

69 e-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), dasabuvir (250 mg t

70 tonavir, fosamprenavir, indinavir, indinavir/ritonavir, and lopinavir/ritonavir were associated with

71 CYP3A4 by ritonavir, subtherapeutic doses of ritonavir are used to increase plasma concentrations of

72 P = .0362) increased more in the atazanavir/ritonavir arm than in darunavir/ritonavir arm.

73 Body fat changes in the atazanavir/ritonavir arm were associated with higher insulin resist

74 e atazanavir/ritonavir arm than in darunavir/ritonavir arm.

75 increase in triglycerides in the atazanavir/ritonavir arm.

76 f the cytochrome P450 3A4 (CYP3A4) inhibitor ritonavir as a pharmacoenhancer for anti-HIV drugs revol

77 luate treatment responses to atazanavir plus ritonavir (ATV/r) or efavirenz (EFV) in initial antiretr

78 ovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r), or ralte

79 rate-emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or RAL.

80 rate/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or ralte

81 o determine if efavirenz (EFV) or atazanavir/ritonavir (ATV/r)-based combination antiretroviral thera

82 smear or PCR findings, between the lopinavir/ritonavir-based and efavirenz-based ART arms (7.4% vs 9.

83 fants starting nevirapine-based vs lopinavir/ritonavir-based antiretroviral regimens.

84 We sought to evaluate whether lopinavir/ritonavir-based antiretroviral therapy (ART) reduced the

85 Lopinavir/ritonavir-based ART did not reduce the risk of placental

86 the IMPAACT P1030 trial receiving lopinavir-ritonavir-based cART.

87 8 and randomly assigned to receive lopinavir/ritonavir-based or efavirenz-based ART.

88 virus-infected patients receiving lopinavir/ritonavir-based regimens with hypercholesterolemia.

89 te ratio 1.14 [95% CI 1.10-1.19], p<0.0001), ritonavir-boosted atazanavir (1.20 [1.13-1.26], p<0.0001

90 600 mg once daily, or 1200 mg once daily or ritonavir-boosted atazanavir (300 mg of atazanavir and 1

91 (TFV) disoproxil fumarate/emtricitabine and ritonavir-boosted atazanavir (ATV) underwent serial pair

92 nd n=50 for the 1200 mg once daily group) or ritonavir-boosted atazanavir (n=51).

93 T (tenofovir [TFV], emtricitabine [FTC], and ritonavir-boosted atazanavir [ATV]) with suppressed plas

94 roups and two (4%) of the 51 patients in the ritonavir-boosted atazanavir group discontinued because

95 instances with no dose relation and for the ritonavir-boosted atazanavir group these were mostly gas

96 ups and five (10%) of the 51 patients in the ritonavir-boosted atazanavir group.

97 compared with 38 (75%) of 51 patients in the ritonavir-boosted atazanavir group.

98 68 groups and 14 (27%) of 51 patients in the ritonavir-boosted atazanavir group.

99 ment-naive adult subjects were randomized to ritonavir-boosted atazanavir or darunavir, or raltegravi

100 lines consider regimens consisting of either ritonavir-boosted atazanavir or ritonavir-boosted lopina

101 avir group) or a three-tablet combination of ritonavir-boosted atazanavir plus coformulated tenofovir

102 oosted darunavir was superior to that of the ritonavir-boosted atazanavir regimen.

103 ir were equivalent for tolerability, whereas ritonavir-boosted atazanavir resulted in a 12.7% and 9.2

104 se (aIRR, 1.18/year [95% CI, 1.12-1.25]) and ritonavir-boosted atazanavir use (aIRR, 1.19/year [95% C

105 with a boosted protease inhibitor regimen of ritonavir-boosted atazanavir with emtricitabine and teno

106 il fumarate (integrase inhibitor regimen) or ritonavir-boosted atazanavir with emtricitabine and teno

107 ritonavir-boosted darunavir was superior to ritonavir-boosted atazanavir, and raltegravir was superi

108 In a comparison with ritonavir-boosted atazanavir, efficacy and safety of BMS

109 f exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, or ritonavir-boosted lopin

110 e exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, ritonavir-boosted lopinavi

111 nd 51 patients received at least one dose of ritonavir-boosted atazanavir.

112 diagnosed with INSTI-R virus, they change to ritonavir-boosted darunavir (DRV/r)-based ART.

113 lvitegravir (EVGcobi), rilpivirine (RPV), or ritonavir-boosted darunavir (DRVrtv).

114 lutegravir group and 164 (68%) of 242 in the ritonavir-boosted darunavir group had HIV-1 RNA less tha

115 ological response rate than did those taking ritonavir-boosted darunavir once daily, with similar tol

116 ombined virologic efficacy and tolerability, ritonavir-boosted darunavir was superior to ritonavir-bo

117 bility of regimens containing raltegravir or ritonavir-boosted darunavir was superior to that of the

118 Raltegravir and ritonavir-boosted darunavir were equivalent for tolerabi

119 ive dolutegravir and 242 assigned to receive ritonavir-boosted darunavir).

120 ability discontinuation than raltegravir and ritonavir-boosted darunavir, respectively, primarily bec

121 concluded that dolutegravir was superior to ritonavir-boosted darunavir.

122 virological response rate than is once-daily ritonavir-boosted darunavir.

123 atazanavir (1.20 [1.13-1.26], p<0.0001), and ritonavir-boosted lopinavir (1.11 [1.06-1.16], p<0.0001)

124 were randomly assigned (1:1) to receive oral ritonavir-boosted lopinavir (100 mg ritonavir, 400 mg lo

125 ching to efavirenz (EFV) versus remaining on ritonavir-boosted lopinavir (LPV/r) for virologic contro

126 not boys) exposed in utero to ZDV/lamivudine/ritonavir-boosted lopinavir (LPV/r) had a higher left ve

127 ull hypothesis that efavirenz is inferior to ritonavir-boosted lopinavir (P < .001) for both end poin

128 ng of either ritonavir-boosted atazanavir or ritonavir-boosted lopinavir and a nucleoside reverse tra

129 sed trial showed that NtRTI-sparing ART with ritonavir-boosted lopinavir and raltegravir (raltegravir

130 vir-group) provided non-inferior efficacy to ritonavir-boosted lopinavir and two or three NtRTIs (NtR

131 -treatment for tuberculosis, preservation of ritonavir-boosted lopinavir for second-line treatment, a

132 he efavirenz group and 0.284 (n = 42) in the ritonavir-boosted lopinavir group.

133 the efavirenz group and 0.020 (n = 3) in the ritonavir-boosted lopinavir group.

134 %) higher in the efavirenz group than in the ritonavir-boosted lopinavir group.

135 g, our data support WHO's recommendation for ritonavir-boosted lopinavir plus NRTI for second-line an

136 Ritonavir-boosted lopinavir plus raltegravir is an appro

137 gravir twice a day (raltegravir group) or to ritonavir-boosted lopinavir plus two or three NRTIs sele

138 l fumarate, ritonavir-boosted atazanavir, or ritonavir-boosted lopinavir therapy.

139 re not significant predictors of CKD whereas ritonavir-boosted lopinavir use was a significant predic

140 boosted protease inhibitor (standardised to ritonavir-boosted lopinavir) with two to three NRTIs (cl

141 iptase inhibitors efavirenz and rilpivirine, ritonavir-boosted lopinavir, and the integrase inhibitor

142 Second-line ART regimens were based on ritonavir-boosted lopinavir, combined with zidovudine or

143 oxil fumarate, ritonavir-boosted atazanavir, ritonavir-boosted lopinavir, other ritonavir-boosted pro

144 favirenz-based therapy (n = 150) or continue ritonavir-boosted lopinavir-based therapy (n = 148).

145 irenz-based therapy compared with continuing ritonavir-boosted lopinavir-based therapy did not result

146 sion and with initial viral suppression with ritonavir-boosted lopinavir-based therapy, switching to

147 sma HIV RNA of less than 50 copies/mL during ritonavir-boosted lopinavir-based therapy; 298 were rand

148 icipants were randomly assigned to receive a ritonavir-boosted protease inhibitor (lopinavir 400 mg w

149 nd first-line treatment failure to receive a ritonavir-boosted protease inhibitor (lopinavir-ritonavi

150 To determine whether treatment with ritonavir-boosted protease inhibitor (PI) monotherapy is

151 Virologic failure (VF) on a first-line ritonavir-boosted protease inhibitor (PI/r) regimen is a

152 A inhibitor ombitasvir coformulated with the ritonavir-boosted protease inhibitor ABT-450 (ABT-450/r)

153 irologically suppressed HIV infection from a ritonavir-boosted protease inhibitor and emtricitabine p

154 o switch to a strategy of physician-selected ritonavir-boosted protease inhibitor monotherapy (PI-mon

155 pressed adults with HIV taking a multitablet ritonavir-boosted protease inhibitor regimen.

156 r mL for at least 6 months who were taking a ritonavir-boosted protease inhibitor with emtricitabine

157 ining condition, longer duration of use of a ritonavir-boosted protease inhibitor, and no prior use o

158 initiated salvage ART including, at least 1 ritonavir-boosted protease inhibitor, raltegravir or etr

159 d-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents

160 de Reverse Transcriptase Inhibitors (EFV) or ritonavir-boosted Protease Inhibitors (PI) with the same

161 okinetic interactions between boceprevir and ritonavir-boosted protease inhibitors (PI/r) was conduct

162 ammation and immune activation compared with ritonavir-boosted protease inhibitors (PIs).

163 (1.11 [1.06-1.16], p<0.0001), but not other ritonavir-boosted protease inhibitors or abacavir.

164 azanavir, ritonavir-boosted lopinavir, other ritonavir-boosted protease inhibitors, or abacavir.

165 toichiometry equal to 0.93 +/- 0.04 moles of ritonavir bound per mole of inactivated CYP3A4.

166 The metabolism of [(3)H]ritonavir by CYP3A4 leads to the formation of a covalent

167 Associations between ritonavir C24 and lipid changes at week 48 were evaluate

168 Ritonavir C24 was not different by arm (P = .89) (median

169 Ritonavir C24 was not different in the PI arms and had n

170 ase inhibitor regimens to treat HIV (such as ritonavir) can result in systemic accumulation of inhale

171 directly posttransplantation in patients on ritonavir-containing cART and raising trough levels to a

172 ttransplantation in HIV-infected patients on ritonavir-containing cART, the predictive value of a pre

173 nofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir.

174 onate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) +/- ribavirin (R

175 - ribavirin (9%) and ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin (6%).

176 with SOF/ledipasvir, ombitasvir/paritaprevir/ritonavir + dasabuvir, and SOF plus daclatasvir was effi

177 fosbuvir/simeprevir, ombitasvir/paritaprevir/ritonavir +/- dasabuvir as well as boceprevir and telapr

178 In contrast, for ombitasvir/paritaprevir/ritonavir +/- dasabuvir potentially significant DDIs cou

179 ombitasvir, 150 mg of ABT-450, and 100 mg of ritonavir), dasabuvir (250 mg twice daily), and ribaviri

180 Ombitasvir-paritaprevir-ritonavir-dasabuvir may cause type B lactic acidosis.

181 d had started taking ombitasvir-paritaprevir-ritonavir-dasabuvir within the preceding 2 weeks, presen

182 rting treatment with ombitasvir-paritaprevir-ritonavir-dasabuvir.

183 asvir/sofosbuvir, or paritaprevir/ombitasvir/ritonavir/dasabuvir during the 18-month period from Janu

184 previr; sofosbuvir; ombitasvir, paritaprevir/ritonavir/dasabuvir; sofosbuvir/ledipasvir; and daclatas

185 plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or RAL.

186 plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r), or raltegravir (RAL) in ACTG A5260s,

187 plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or raltegravir (RAL).

188 navir/ritonavir and 5 discontinued darunavir/ritonavir due to adverse effects.

189 the commonly used antiretrovirals darunavir/ritonavir, efavirenz, and tenofovir to guide the coadmin

190 se transport with the HIV protease inhibitor ritonavir elicited growth arrest and/or apoptosis in mul

191 glucose metabolism with the GLUT4 inhibitor ritonavir elicits variable cytotoxicity in MM that is ma

192 In conclusion, ritonavir exhibited potent time-dependent inactivation o

193 However, owing to higher paritaprevir and/or ritonavir exposures, evening administration of atazanavi

194 udine, emtricitabine/tenofovir, or lopinavir/ritonavir for 7 or 21 days.

195 tenofovir/emtricitabine (FTC), or lopinavir/ritonavir for either 7 or 21 days.

196 c drugs investigated, atazanavir, atazanavir/ritonavir, fosamprenavir, indinavir, indinavir/ritonavir

197 ritonavir (ombitasvir plus paritaprevir plus ritonavir), given with or without ribavirin.

198 ir group and 13 (four) in the darunavir plus ritonavir group discontinued because of adverse events.

199 group vs 57/242 [24%] in the darunavir plus ritonavir group), nausea (31/242 [13%] vs 34/242 [14%]),

200 uble CD14, and longer prior use of high-dose ritonavir (>/=400 mg/24 hours) were each also associated

201 200 (83%) patients receiving darunavir plus ritonavir had HIV-1 RNA of less than 50 copies per mL (a

202 nds (15a and 15b) that are less complex than ritonavir have comparable submicromolar affinity and inh

203 is capable of detecting 100 ppm crystalline ritonavir in an amorphous hydroxypropyl methylcellulose

204 s between atazanavir/ritonavir and darunavir/ritonavir in efficacy, clinically relevant side effects,

205 to a large extend by the coadministration of ritonavir in HIV-infected transplant recipients.

206 we compared dolutegravir with darunavir plus ritonavir in individuals naive for antiretroviral therap

207 ata suggests multiple types of inhibition by ritonavir, including mechanism-based inactivation by met

208 Tryptic digestion of the CYP3A4-[(3)H]ritonavir incubations exhibited an adducted peptide (255

209 tion and associated systemic inflammation of ritonavir-induced atherosclerotic in ApoE(-/-) mice and

210 Ritonavir is a human immunodeficiency virus (HIV) protea

211 3-DAA combination of simeprevir + TMC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus ge

212 However, atazanavir/ritonavir led to higher triglycerides and more total and

213 PIs (ritonavir, lopinavir, and atazanavir) but not nucleoside

214 xposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease i

215 al components by 2.1- to 3.4-fold; lopinavir/ritonavir (LPV/r) increased lumefantrine exposure by 2.1

216 CTG) A5230 study entry, a study of lopinavir/ritonavir (LPV/r) monotherapy after first-line virologic

217 Group (ACTG) A5230 study evaluated lopinavir/ritonavir (LPV/r) monotherapy following virologic failur

218 <6 years of age were randomized to lopinavir/ritonavir (LPV/r) or nonnucleoside reverse transcriptase

219 nstrated short-term superiority of lopinavir/ritonavir (LPV/r) over nevirapine (NVP) in antiretrovira

220 Three randomized trials compared lopinavir/ritonavir (LPV/r) to nevirapine (NVP) for antiretroviral

221 ranscriptase inhibitor (NNRTI)- or lopinavir/ritonavir (LPV/r)-based regimen were enrolled.

222 regimens (TDF+emtricitabine [FTC]+lopinavir/ritonavir [LPV/r], 71.1%; 95% CI, 43.6%-98.6%; TDF+FTC+r

223 Calpain inhibition by ritonavir may be a powerful tool for preserving neurons

224 t that the HIV protease inhibitors lopinavir/ritonavir may have potent antimalarial activity.

225 riptase inhibitors associated with darunavir/ritonavir (n = 12), saquinavir/ritonavir (n = 2), and ma

226 ith darunavir/ritonavir (n = 12), saquinavir/ritonavir (n = 2), and maraviroc (n = 3).

227 ere demonstrate that inhibition of CYP3A4 by ritonavir occurs by CYP3A4-mediated activation and subse

228 50), an NS3/4A protease inhibitor dosed with ritonavir (ombitasvir plus paritaprevir plus ritonavir),

229 e regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a

230 with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, con

231 whether ribavirin is necessary for ABT-450, ritonavir, ombitasvir, and dasabuvir to produce high rat

232 The interferon-free regimen of ABT-450, ritonavir, ombitasvir, and dasabuvir, with or without ri

233 gned randomly (1:1) to groups given ABT-450, ritonavir, ombitasvir, and dasabuvir, with ribavirin (gr

234 study to quantify the effect of paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) and ledipasvir/s

235 vir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) in treatment o

236 twice daily plus 800 mg darunavir and 100 mg ritonavir once daily (NtRTI-sparing regimen) or tenofovi

237 once daily, plus 800 mg darunavir and 100 mg ritonavir once daily (standard regimen).

238 azanavir (300 mg of atazanavir and 100 mg of ritonavir once daily), each with 400 mg of raltegravir t

239 ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir once daily, with weight-based ribavirin dosed

240 e observed between faldaprevir and darunavir/ritonavir or tenofovir.

241 respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor.

242 ine regimens containing efavirenz, darunavir/ritonavir, or raltegravir regardless of pretreatment vir

243 plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir.

244 ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir orally once daily plus weight-based ribavirin.

245 atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before base

246 ed using sofosbuvir/ledipasvir or ombitasvir/ritonavir/paritaprevir/dasabuvir to treat: (1) any patie

247 atazanavir/ritonavir and 62 (71%) darunavir/ritonavir patients remained free of treatment failure (e

248 atazanavir/ritonavir and 75 (85%) darunavir/ritonavir patients remained free of virological failure

249 diochromatic peak and a mass consistent with ritonavir plus 16 Da, in agreement with the whole-protei

250 ne compared to triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides for maintenance of human

251 DV/SOF +/- RBV) and ombitasvir/ paritaprevir/ritonavir plus dasabuvir (OPrD) +/- RBV in HIV/HCV genot

252 aclatasvir, or ombitasvir, paritaprevir, and ritonavir plus dasabuvir are suitable.

253 ated whether dual therapy with lopinavir and ritonavir plus lamivudine is non-inferior to standard tr

254 Dual therapy with lopinavir and ritonavir plus lamivudine regimen warrants further clini

255 treatment with ombitasvir, paritaprevir, and ritonavir plus ribavirin beyond 12 weeks seems to have n

256 Ombitasvir, paritaprevir, and ritonavir plus ribavirin for 12 weeks achieved SVR12 in

257 treatment with ombitasvir, paritaprevir, and ritonavir plus ribavirin.

258 onavir-boosted protease inhibitor (lopinavir-ritonavir) plus clinician-selected NRTIs (NRTI group, 42

259 ir (NS3/4A protease inhibitor; co-dosed with ritonavir) plus ribavirin in patients with HCV genotype

260 inistered as 150 mg of ABT-450 and 100 mg of ritonavir) plus ribavirin, the rate of sustained virolog

261 treatment with ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin in patients

262 d coformulated ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin, for 12 wee

263 Treatment with ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin, for 8 week

264 vir, an NS3/4A protease inhibitor dosed with ritonavir, plus ribavirin in treatment of chronic HCV in

265 bination with an NS3 protease inhibitor with ritonavir (r) (ABT-450/r) and an NS5B non-nucleoside pol

266 ning atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recommended in combination wi

267 er, the mechanism of inhibition of CYP3A4 by ritonavir remains unclear.

268 2-DAA) combination of simeprevir + TMC647055/ritonavir +/- ribavirin and of the 3-DAA combination of

269 arunavir (DRV) 600 mg twice daily, each with ritonavir (RTV) 100 mg on days 10-31, plus concomitant b

270 Ritonavir (RTV) and atazanavir (ATV) were co-formulated

271 luate the efficacy and safety of COBI versus ritonavir (RTV) as a pharmacoenhancer of atazanavir (ATV

272 granules and a fixed-dose combination of LPV/ritonavir (RTV) ISNP granules, were prepared using the I

273 with atazanavir (ATV) with or without (+/-) ritonavir (RTV) or standard of care (SOC) (tenofovir dis

274 have been observed when telaprevir (TVR) and ritonavir (RTV)-boosted human immunodeficiency virus (HI

275 Given the potent inhibition of CYP3A4 by ritonavir, subtherapeutic doses of ritonavir are used to

276 between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly.

277 5; 95% CI, 1.04-1.27); TDF-FTC and lopinavir-ritonavir (TDF-FTC-LPV-R) (112 of 231 [48.5%]; ARR, 1.31

278 (four [2%] patients) than for darunavir plus ritonavir (ten [4%] patients) and contributed to the dif

279 ; or tenofovir, emtricitabine, and lopinavir-ritonavir (tenofovir-based ART).

280 ults with HIV initiating ART with atazanavir/ritonavir + tenofovir/emtricitabine to a single zoledron

281 In contrast to ritonavir, the binding affinity of N-methylritonavir for

282 with those who were switched from lopinavir/ritonavir to atazanavir/ritonavir.

283 Ritonavir treatment significantly reduced calpain activi

284 CTG) A5257 study, and correlated with plasma ritonavir trough concentrations (C24).

285 tion, immune activation, and prior high-dose ritonavir use.

286 atio [aOR], 1.95; 95% CI, 1.24-3.05) and for ritonavir used as a booster (aOR, 1.56; 95% CI, 1.11-2.2

287 irus were treated with the FDA-approved drug ritonavir using a dosing regimen that resulted in plasma

288 and 3A5, the structure of 3A5 complexed with ritonavir was determined by X-ray crystallography to a l

289 The trial was open-label, and ritonavir was not provided.

290 Also, fat gains with atazanavir/ritonavir were associated with insulin resistance.

291 x and random assignment to receive lopinavir/ritonavir were associated with more rapid nevirapine eli

292 ndinavir, indinavir/ritonavir, and lopinavir/ritonavir were associated with suboptimal adherence, and

293 showed intermediate resistance to darunavir/ritonavir, whereas high-level resistance was not observe

294 CYP3A4 with N-methylritonavir, an analog of ritonavir, widely used as a pharmacoenhancer.

295 Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) +/- ribavirin

296 regimen of ombitasvir plus paritaprevir plus ritonavir with or without ribavirin achieved high sustai

297 Incubations of [(3)H]ritonavir with reconstituted CYP3A4 and human liver micr

298 2 received ombitasvir plus paritaprevir plus ritonavir with ribavirin, and 49 treatment-experienced p

299 bursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin

300 lone); zidovudine, lamivudine, and lopinavir-ritonavir (zidovudine-based ART); or tenofovir, emtricit